Overview
Join leading experts for a half-day virtual webinar exploring practical strategies to accelerate pulmonary therapeutic development.
Pulmonary drug development is advancing rapidly, but scientific and regulatory uncertainty continues to challenge development decisions.
From biomarkers and endpoints to patient selection, real-world evidence, and regulatory strategy, teams must make critical decisions long before the evidence is complete.
Through expert presentations, real-world case studies, and interactive panel discussions, you'll gain actionable insights to strengthen development programs and bring innovative therapies to patients faster.
Session Topics
Each session will be approximately 75 minutes (45 minutes of presentations followed by a 30-minute panel discussion and audience Q&A)
Session 1: Leveraging Registry Data to Inform Trial Design & Evidence Generation
Examine how pulmonary disease registries and real-world data can strengthen evidence generation, optimize clinical trial design, support regulatory decision-making, and accelerate the development of innovative therapies across pulmonary diseases.
Session 2: Precision Medicine and Fit-for-Purpose Biomarkers
Explore how precision medicine, biomarkers, and companion diagnostics are advancing pulmonary drug development by enabling more targeted therapies, improving patient selection, supporting novel endpoints, and generating evidence to inform regulatory decision-making.
Session 3: First-in-Class, Endpoints, Game Changers, Reinvigorators
Feature success stories that have transformed pulmonary therapeutic development, highlighting first-in-class therapies, novel endpoints, indication expansion, and other innovative strategies that accelerated development and regulatory approval.
Secure your Spot
September 28, 2026 | 9:00am - 2:30pm ET | Virtual - Zoom